Key Points
- David Malcom Rodman sold 417 shares of Mineralys on Feb. 17 at $27.59 for $11,505.03, leaving him with 44,089 shares (a 0.94% drop in his ownership).
- Rodman has been selling repeatedly since early January, offloading approximately 313,754 shares across multiple transactions for a total of just over $10.8 million in proceeds.
- Mineralys (NASDAQ:MLYS) trades around $27.94 with a 1‑year range of $8.24–$47.65, a market cap of $2.21B, and a consensus analyst price target of $47.43 (average rating: "Moderate Buy").
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 417 shares of the company's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $27.59, for a total transaction of $11,505.03. Following the completion of the sale, the insider owned 44,089 shares of the company's stock, valued at $1,216,415.51. This represents a 0.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
David Malcom Rodman also recently made the following trade(s):
- On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $28.99, for a total value of $184,057.51.
- On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.44, for a total value of $385,669.20.
- On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $30.21, for a total value of $65,585.91.
- On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.10, for a total value of $13,353.60.
- On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.61, for a total value of $370,677.87.
- On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.75, for a total value of $252,469.75.
- On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.32, for a total value of $205,167.36.
- On Friday, January 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $33.27, for a total value of $72,195.90.
- On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.87, for a total transaction of $2,512,227.19.
- On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $35.02, for a total transaction of $6,748,879.30.
Mineralys Therapeutics Trading Up 1.2%
NASDAQ:MLYS opened at $27.94 on Wednesday. Mineralys Therapeutics, Inc. has a 1 year low of $8.24 and a 1 year high of $47.65. The firm's fifty day simple moving average is $33.50 and its 200 day simple moving average is $33.87. The firm has a market capitalization of $2.21 billion, a PE ratio of -9.47 and a beta of 0.51.
Analyst Ratings Changes
A number of equities analysts have recently commented on the company. HC Wainwright lifted their price objective on Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a "buy" rating in a research note on Wednesday, November 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Mineralys Therapeutics in a report on Thursday, January 22nd. Stifel Nicolaus upped their price target on Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a report on Friday, December 19th. Finally, Wells Fargo & Company increased their price objective on Mineralys Therapeutics from $50.00 to $55.00 and gave the company an "overweight" rating in a research report on Tuesday, November 11th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $47.43.
View Our Latest Report on Mineralys Therapeutics
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. RA Capital Management L.P. lifted its position in shares of Mineralys Therapeutics by 19.1% during the 3rd quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company's stock worth $277,717,000 after buying an additional 1,176,470 shares during the period. Vanguard Group Inc. increased its stake in shares of Mineralys Therapeutics by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 3,352,880 shares of the company's stock valued at $121,676,000 after buying an additional 333,881 shares in the last quarter. State Street Corp raised its holdings in shares of Mineralys Therapeutics by 144.4% in the fourth quarter. State Street Corp now owns 3,184,999 shares of the company's stock valued at $115,584,000 after buying an additional 1,881,976 shares during the last quarter. Caligan Partners LP lifted its position in Mineralys Therapeutics by 37.4% during the 3rd quarter. Caligan Partners LP now owns 2,772,654 shares of the company's stock worth $105,139,000 after buying an additional 755,302 shares in the last quarter. Finally, Suvretta Capital Management LLC grew its holdings in Mineralys Therapeutics by 22.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 2,132,133 shares of the company's stock worth $80,850,000 after acquiring an additional 387,641 shares during the last quarter. Institutional investors and hedge funds own 84.46% of the company's stock.
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
